Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).

Elayta (zervimesine) - Cognition Therap

http://www.ncbi.nlm.nih.gov/pubmed/41416579

Anthony O Caggiano; Douglas W Scharre; James E Galvin; Jennifer F Iaci; Magdalena I Tolea; Mary E Hamby; Michael Grundman

Dec 19, 2025